Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma
Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma Harpoon Therapeutics, Inc. a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma. HPN217, a tri-specific T cell activating recombinant protein construct targets B-cell maturation antigen a well-validated antigen expressed on malignant multiple … Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunother...
Source: investingnews.com